Effects of DC-CIK cell immunotherapy combined with chemotherapy on immune function, coagulation function and tumor stem cell markers in patients with recurrent ovarian cancer

摘要

Objective: To investigate the effects of immunotherapy with dendritic cells (DC)-cytokineinduced killer cells (CIK) combined with chemotherapy on immune function, coagulationfunction and tumor stem cell markers in patients with recurrent ovarian cancer. Methods: Atotal of 80 cases in our hospital for treatment of recurrent ovarian cancer patients were selectedas the research object, they were divided into chemotherapy group (n=35) and combinedtreatment group (n=45) according to whether or not to receive cellular immunotherapy,chemotherapy group received TC chemotherapy, combined therapy group were given DC-CIKcell immunotherapy combined with TC chemotherapy group, the two groups were treated with21 d for a cycle, 3 cycles were treated; The changes of immune function, coagulation functionand tumor stem cell markers were compared between the day of blood collection and theend of treatment for 7 d. Results: After the end of treatment for 7 d, the CD3+, CD3+CD4+,CD4+/CD8+, NK cell number of combined treatment group were significantly higher than thatof blood collection day, the number of CD4+ CD25+ was significantly lower than that of bloodcollection day, The improvement of peripheral blood T lymphocyte subsets in the combinedtreatment group was better than that in the chemotherapy group; After the end of treatment for7 d, the FIB levels of two groups were significantly decreased than those of the blood collectionday, the difference was statistically significant; After the end of treatment for 7 d, the CD133and DDX4 levels of two groups were significantly lower than that of the blood collection day,and the combined treatment group was significantly lower than the chemotherapy group, thedifference were statistically significant. Results: DC-CIK cell immunotherapy combined withchemotherapy can significantly improve the immunity and the level of FIB of patients withrecurrent ovarian cancer, and regulating the level of serum tumor stem cell markers in patients,it has positive significance to improve the prognosis of patients, and is worthy of popularizationand application in clinic.